A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 109-111

  Sistonen, Johanna ^a   Smith, Chingying ^b   Fu, Yung Kang ^b   Largiadèr, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b AutoGenomics Inc   (United States)

Author keywords

5 Fluorouracil; DPYD; Genotyping; Microarray; Pharmacogenomics

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ALLELE; ALTERNATIVE MEDICINE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; DNA HYBRIDIZATION; DNA MICROARRAY; DPYD GENE; DRUG SAFETY; EUROPEAN; GENE SEQUENCE; GENE TARGETING; GENETIC RISK; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; GENETICS; GENOTYPE; SAFETY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; SAFETY;

EID: 84866478556     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.08.015     Document Type: Article

References (16)

1. Amstutz, U., Froehlich, T.K., Largiader, C.R., Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12 (2011), 1321–1336.
2. Johnson, M.R., Wang, K., Diasio, R.B., Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8 (2002), 768–774.
3. Morel, A., Boisdron-Celle, M., Fey, L., et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5 (2006), 2895–2904.
4. Schwab, M., Zanger, U.M., Marx, C., et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26 (2008), 2131–2138.
5. Vreken, P., Van Kuilenburg, A.B., Meinsma, R., et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis 19 (1996), 645–654.
6. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J., Fernandez-Salguero, P., Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98 (1996), 610–615.
7. Amstutz, U., Farese, S., Aebi, S., Largiader, C.R., Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10 (2009), 931–944.
8. van Kuilenburg, A.B., Meijer, J., Mul, A.N., et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128 (2010), 529–538.
9. The 1000 Genomes Project. http://www.1000genomes.org/ (Accessed May 2012).
10. Common terminology criteria for adverse events v4.03 (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed May 2012).
11. Vairavan, R., AutoGenomics, Inc. Pharmacogenomics 5 (2004), 585–588.
12. Di Francia, R., Berretta, M., Catapano, O., Canzoniero, L.M., Formisano, L., Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications. Clin Chem Lab Med 49 (2011), 1105–1111.
13. Relling, M.V., Klein, T.E., CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89 (2011), 464–467.
14. Deenen, M.J., Tol, J., Burylo, A.M., et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17 (2011), 3455–3468.
15. van Kuilenburg, A.B., Hausler, P., Schalhorn, A., et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 51 (2012), 163–174.
16. Gamelin, E., Delva, R., Jacob, J., et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 2099–2105.